Comparison with overall VEGF levels (measured by ELISA) within the tumours suggested that the increased uptake of 111In-bevacizumab was associated with an increase in VEGF (Fig. 6a) (from 283 ± 56 to 419 ± 47 pg/g of protein) measured by ELISA; however, this did not reach statistical significance (P = 0.07). The gene discussed is VEGFA; the disease is neoplasm.